Kuehne + Nagel chosen as partner for AstraZeneca

 Kuehne + Nagel chosen to provide cold chain services to AstraZeneca

world’s leading international pharmaceutical companies has

selected Kuehne + Nagel to handle part of its exports of

temperature-sensitive pharmaceutical products from Europe

to the rest of the world.

Under the new agreement, Kuehne + Nagel will supply a complete

solution for the transportation by air and sea of products indicated for

therapeutic categories including oncology and anaesthetics, as well as

active pharmaceutical ingredients.

Kuehne + Nagel’s range of air- and seafreight solutions will meet the

regulatory requirements for exports from AstraZeneca production sites

in the UK, Sweden, France, Italy and Germany to further production

sites and regional distribution centres in the Middle East, Japan, Africa

and the USA. AstraZeneca will benefit from full visibility of shipments

via Kuehne + Nagel’s online system, KN Login.

In addition, the pharmaceutical products, which are in both emulsion

and solid form, must be maintained within a stipulated temperature

range. In order to achieve this, Kuehne + Nagel has developed robust,

cutting-edge cold chain packaging solutions that will deliver product

integrity and compliance in line with the MHRA’s* Good Distribution

Practice.

“We completed a thorough tendering process from which Kuehne +

Nagel emerged as one of our preferred suppliers. They were selected

based on the pricing offered, their company culture and the speed with

which we could implement together our new way of working. I have

been very pleased by the energy which Kuehne + Nagel have applied

to cutting over the current arrangements and also proposing potential

new solutions,” said James Shaw, AstraZeneca Global Freight and

Logistics Manager.

“Kuehne + Nagel offers extensive global experience in the

pharmaceutical sector“, added Peter Ulber, Chief Executive of Kuehne

+ Nagel, North West Europe. “We are able to meet the challenges of

this particular industry through innovation and investment in marketspecific

solutions, such as door-to-door cold chain solutions and packaging, while also offering our customer economies of scale due to

our global reach.”

Notes to Editors

*MHRA – Medicines and Healthcare products Regulatory Agency.